Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
FeedbackLSE:FDBK +0.83% Debt-to-Equity is 0.00 as of Nov. 2025. The stock has 4 warning signs investors should review. Among 559 Healthcare Providers & Services companies, Feedback ranks worse than 178890.7% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Feedback's Debt-to-Equity or its related term are showing as below:
LSE:FDBK's Debt-to-Equity is not ranked *
in the Healthcare Providers & Services industry.
Industry Median: 0.42 * Ranked among companies with meaningful Debt-to-Equity only.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Feedback Debt-to-Equity Related Terms
Feedback Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Feedback's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LSE:FDBK vs VEEV, BTSG, HQY: Debt-to-Equity Comparison
For the Health Information Services subindustry, Feedback's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Feedback Debt-to-Equity vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Feedback's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Feedback's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Feedback (LSE:FDBK) has a Debt-to-Equity of 0.00 as of Nov. 2025. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Feedback and its competitors. According to the industry distribution chart, Feedback ranks #999999 out of 559 companies in the Healthcare Providers & Services industry.
Is Feedback's Debt-to-Equity too high?
Feedback's current Debt-to-Equity is 0.00. Based on the distribution chart, Feedback ranks #999999 out of 559 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers.
How does Feedback's Debt-to-Equity compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Feedback ranks #999999 out of 559 companies for Debt-to-Equity. This places Feedback in the lower half of its industry. The industry median Debt-to-Equity is 0.42. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Healthcare Providers & Services company?
The median Debt-to-Equity among Healthcare Providers & Services companies is 0.42, based on 559 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Feedback and its competitors. For the Healthcare Providers & Services industry, the median Debt-to-Equity is 0.42 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Feedback's current Debt-to-Equity is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Feedback stock overvalued right now?
Based on GuruFocus' analysis, Feedback (LSE:FDBK) is currently considered Possible Value Trap. The stock's GF Value™ is £0.14, compared to a current price of £0.06 — trading 56.4% below its estimated fair value. The current Debt-to-Equity is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Feedback (LSE:FDBK), the current Debt-to-Equity is 0.00 as of Nov. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Feedback PLC is a medical imaging software and tools company. It develops and markets imaging tools and software for clinical decision-making, and also techniques and improved workflow for medical practitioners engaged in research and in treating patients. Its operating segments include Medical Imaging and Feedback Medical Imaging India. Its products include Bleepa, a regulated communication platform for sharing clinical results and supporting multidisciplinary teamwork, and CareLocker, a patient-facing platform that provides access and control over diagnostic and clinical data.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LSE:FDBK has been successfully added to your 
